FDA Approves Regeneron’s ARCALYST™ (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) First therapy approved for this rare, hereditary, inflammatory disease Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time
Friday, February 29, 2008 1 min read
Key Takeaway: FDA Approves Regeneron’s ARCALYST™ (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) First therapy approved for this rare, hereditary, inflammatory disease Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time
Full Press Release Details
FDA Approves Regeneron’s ARCALYST™ (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) First therapy approved for this rare, hereditary, inflammatory disease Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time.